Compare First Horizon Corporation Common Stock (FHN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Horizon Corporation Common Stock vs Natera Inc. Common Stock — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.3× First Horizon Corporation Common Stock's market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and Natera Inc. Common Stock for 0 Days on average.
| FHN | NTRA | |
|---|---|---|
Market Cap | $10.79B | $57.03B |
Volume | 8,579,466 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $26.23 | $425.64 |
52-Week Low | $19.94 | $179.42 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.10B | $56.18B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Horizon Corporation Common Stock
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
